<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079114</url>
  </required_header>
  <id_info>
    <org_study_id>09H07</org_study_id>
    <nct_id>NCT04079114</nct_id>
  </id_info>
  <brief_title>Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System</brief_title>
  <official_title>Post Market Clinical Follow-Up Study of the Zimmer Stafit Acetabular System. A Multicenter, Prospective, Non-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Post Market Clinical Follow up study to fulfil the post market surveillance
      obligations according to Medical Device Directive and European Medical Device Vigilance
      System (MEDDEV) 2.12-2. The data collected from this study will serve the purpose of
      confirming safety and performance of the Zimmer Stafit Acetabular System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to obtain implant survival and outcome data on the Stafit
      Acetabular System by analysis of standard scoring systems, radiographs, and adverse event
      records.

      Data will be used to monitor pain, mobility, dislocation rate and implant survival, and to
      confirm the long-term safety and performance of the Stafit Acetabular System in primary total
      hip arthroplasty.

      The study design is a multi-center, prospective, non-controlled, consecutive cohort post
      market clinical follow-up study, involving orthopedic surgeons skilled in total hip
      arthroplasty procedures and experienced with the Stafit Acetabular System.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stafit Acetabular System not CE marked anymore
  </why_stopped>
  <start_date type="Actual">April 28, 2011</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 24, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Survival</measure>
    <time_frame>3 years postoperatively, due to early study termination</time_frame>
    <description>Represents the implants that survived by counting the number of implants revised.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dislocation Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by counting the number of implant dislocations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</measure>
    <time_frame>3 years postoperatively, due to early study termination</time_frame>
    <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed for walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a minimum of 0 (worst possible score) to a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of Safety Based on Complications</measure>
    <time_frame>3 years postoperatively, due to early study termination</time_frame>
    <description>Reported number of patients with adverse events related to the implant. Adverse events include: dislocations of the hip, revisions and removals of the implants</description>
  </secondary_outcome>
  <enrollment type="Actual">166</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Fracture of Hip</condition>
  <condition>Avascular Necrosis of Hip</condition>
  <condition>Dislocated Hip</condition>
  <condition>Osteonecrosis</condition>
  <condition>Post-traumatic; Arthrosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Subluxation Hip</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patients who received the Stafit Acetabular System</intervention_name>
    <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, suffering from severe hip pain and disability, requiring primary total hip
        arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Patients suffering from severe hip pain and disability requiring a primary total hip
             arthroplasty.

          -  18 years minimum

          -  Patients able to participate in a follow-up program based upon physical examination
             and medical history

          -  Patients who have provided written informed consent by signing the Patient Informed
             Consent Form.

        Exclusion Criteria:

          -  Patients who are unwilling or unable to give informed consent, or to comply with the
             follow-up program

          -  Known pregnancy

          -  Revision hip arthroplasty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Paola Vivoda</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <results_first_submitted>April 15, 2020</results_first_submitted>
  <results_first_submitted_qc>June 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2020</results_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04079114/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Who Received the Stafit Acetabular System</title>
          <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study prematurely terminated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study prematuely terminated.</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Who Received the Stafit Acetabular System</title>
          <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Implant Survival</title>
        <description>Represents the implants that survived by counting the number of implants revised.</description>
        <time_frame>3 years postoperatively, due to early study termination</time_frame>
        <population>Outcome Measure Data at 3 years postoperative (Study early terminated). The Kaplan-Meier survival rate with cup revision for any reason.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Received the Stafit Acetabular System</title>
            <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival</title>
          <description>Represents the implants that survived by counting the number of implants revised.</description>
          <population>Outcome Measure Data at 3 years postoperative (Study early terminated). The Kaplan-Meier survival rate with cup revision for any reason.</population>
          <units>percentage of implant survival</units>
          <param>Number</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dislocation Rate</title>
        <description>Assessed by counting the number of implant dislocations</description>
        <time_frame>2 years</time_frame>
        <population>Count of the number of dislocations 2 years postoperatively.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Received the Stafit Acetabular System</title>
            <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Dislocation Rate</title>
          <description>Assessed by counting the number of implant dislocations</description>
          <population>Count of the number of dislocations 2 years postoperatively.</population>
          <units>Implant Dislocations</units>
          <param>Number</param>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</title>
        <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed for walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a minimum of 0 (worst possible score) to a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
        <time_frame>3 years postoperatively, due to early study termination</time_frame>
        <population>Outcome Measure Data at 3 years postoperative (Study early terminated). Number Of Unilateral Participants: 48 Unilaterals; Number Of Bilateral Participants : 1</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Received the Stafit Acetabular System</title>
            <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</title>
          <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed for walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a minimum of 0 (worst possible score) to a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
          <population>Outcome Measure Data at 3 years postoperative (Study early terminated). Number Of Unilateral Participants: 48 Unilaterals; Number Of Bilateral Participants : 1</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmation of Safety Based on Complications</title>
        <description>Reported number of patients with adverse events related to the implant. Adverse events include: dislocations of the hip, revisions and removals of the implants</description>
        <time_frame>3 years postoperatively, due to early study termination</time_frame>
        <population>Outcome Measure Data at 3 years postoperative (Study early terminated). Record of any adverse events related to the Stafit Acetabular System.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Received the Stafit Acetabular System</title>
            <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmation of Safety Based on Complications</title>
          <description>Reported number of patients with adverse events related to the implant. Adverse events include: dislocations of the hip, revisions and removals of the implants</description>
          <population>Outcome Measure Data at 3 years postoperative (Study early terminated). Record of any adverse events related to the Stafit Acetabular System.</population>
          <units>study patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>follow-up visits at 6-12 weeks, 1, 2, and up to 3 years postoperatively.</time_frame>
      <desc>List of all the adverse events reported until the early study termination (some patients came until 3 year follow-up).</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients Who Received the Stafit Acetabular System</title>
          <description>Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death (Stroke)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Treated by lavage and antibiotic.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Deep Infection &lt;6 Weeks</sub_title>
                <description>Treated by lavage and antibiotic.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Treated by 2 Red cell transfusion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Femoral Implant Fracture</sub_title>
                <description>Treated by change of the Stem</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Treated by Lavage and antibiotic</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Treated by change of the heart treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Deep Infection &lt;6 Weeks</sub_title>
                <description>Treated by lavage and antibiotic</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Suspicion infection</sub_title>
                <description>Hospitalization</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoarthrosis</sub_title>
                <description>Treated by implantation of a nail.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Axonal mononeuropathy</sub_title>
                <description>Treated by move of the knee.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peroperative fracture of the femur</sub_title>
                <description>Treated by peroperative cerclage of the femur.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fracture femur</sub_title>
                <description>Treated by plate osteosynthesis.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total Knee Arthroplasty Left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fracture of Trochanter</sub_title>
                <description>Treated by Cerclage</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Injury</sub_title>
                <description>Treated by suture and vascular surgical exploration</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early study termination leading less patients enrolled and shorter follow-up as initially planned in the study protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emilie Rohmer, Clinical Operations Manager</name_or_title>
      <organization>Zimmer Biomet</organization>
      <phone>+41 58 85 48210</phone>
      <email>Emilie.Rohmer@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

